Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia

Kristen Tropea, Helen Christou, Kristen Tropea, Helen Christou

Abstract

Bronchopulmonary dysplasia (BPD) is a major complication of preterm birth and has serious adverse long-term health consequences. The etiology of BPD is complex, multifactorial, and incompletely understood. Contributing factors include ventilator-induced lung injury, exposure to toxic oxygen levels, and infection. Several preventive and therapeutic strategies have been developed with variable success. These include lung protective ventilator strategies and pharmacological and nutritional interventions. These strategies target different components and stages of the disease process and they are commonly used in combination. The purpose of this review is to discuss the evidence for current pharmacological interventions and identify future therapeutic modalities that appear promising in the prevention and management of BPD. Continued improved understanding of BPD pathogenesis leads to opportunities for newer preventive approaches. These will need to be evaluated in the setting of current clinical practice in order to assess their efficacy.

References

    1. Goldenberg RL, Jobe AH. Prospects for research in reproductive health and birth outcomes. Journal of the American Medical Association. 2001;285(5):633–639.
    1. Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117(3):S52–S56.
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. 2001;163(7):1723–1729.
    1. Laughon MM, Brian Smith P, Bose C. Prevention of bronchopulmonary dysplasia. Seminars in Fetal and Neonatal Medicine. 2009;14(6):374–382.
    1. Eichenwald EC, Stark AR. Management and outcomes of very low birth weight. New England Journal of Medicine. 2008;358(16):1662–1711.
    1. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database of Systematic Reviews. 2001;(3) Article ID CD000140.
    1. Barrington K, Finer N. The natural history of the appearance of apnea of prematurity. Pediatric Research. 1991;29(4 I):372–375.
    1. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. New England Journal of Medicine. 2006;354(20):2112–2121.
    1. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. New England Journal of Medicine. 2007;357(19):1893–1902.
    1. Baveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Seminars in Perinatology. 2006;30(4):209–218.
    1. Brown ER, Stark A, Sosenko I. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. Journal of Pediatrics. 1978;92(6):982–984.
    1. Van Marter LJ, Leviton A, Allred EN, Pagano M, Kuban KCK. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. Journal of Pediatrics. 1990;116(6):942–949.
    1. Carpenter TC, Stenmark KR, Boeckh MJ, Gern JE. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatric Infectious Disease Journal. 2004;23(1, supplement):S33–S40.
    1. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2000;(2) Article ID CD001453.
    1. Najak ZD, Harris EM, Lazzara A, Pruitt AW. Pulmonary effects of furosemide in preterm infants with lung disease. Journal of Pediatrics. 1983;102(5):758–763.
    1. McCann EM, Lewis K, Deming DD. Controlled trial of furosemide therapy in infants with chronic lung disease. Journal of Pediatrics. 1985;106(6):957–962.
    1. Rush MG, Engelhardt B, Parker RA, Hazinski TA. Double-blind placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. Journal of Pediatrics. 1990;117(1 I):112–118.
    1. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2000;(2) Article ID CD001694.
    1. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2002;(1) Article ID CD001817.
    1. Kao LC, Durand DJ, McCrea MRC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. Journal of Pediatrics. 1994;124(5):772–781.
    1. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. Journal of Pediatrics. 1989;115(4):615–620.
    1. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. Journal of Perinatology. 2000;20(1):41–45.
    1. Ng GY, da S, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2001;(3) Article ID CD003214.
    1. Kirpalani H, Koren G, Schmidt B, Tan Y, Santos R, Soldin S. Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia. Critical Care Medicine. 1990;18(12):1374–1377.
    1. Gappa M, Gärtner M, Poets CF, Von Der Hardt H. Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease. Pediatric Pulmonology. 1997;23(6):442–448.
    1. Pfenninger J, Aebi C. Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection. Intensive Care Medicine. 1993;19(5):251–255.
    1. Silverman EK, Kwiatkowski DJ, Sylvia JS, et al. Family-based association analysis of β2-adrenergic receptor polymorphisms in the Childhood Asthma Management Program. Journal of Allergy and Clinical Immunology. 2003;112(5):870–876.
    1. Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics. 2002;3(2):173–184.
    1. Lee DKC, Bates CE, Lipworth BJ. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous β2-adrenoceptor haplotypes at positions 16 and 27. British Journal of Clinical Pharmacology. 2004;57(1):100–104.
    1. Denjean A, Paris-Llado J, Zupan V, et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. European Journal of Pediatrics. 1998;157(11):926–931.
    1. Davis JM, Sinkin RA, Aranda JV. Drug therapy for bronchopulmonary dysplasia. Pediatric Pulmonology. 1990;8(2):117–125.
    1. Roberts JM, Jacobs MM, Cheng JB, Barnes PJ, O’Brien AT, Ballard PJ. Fetal pulmonary beta-adrenergic receptors: characterization in the human and in vitro modulation by glucocorticoids in the rabbit. Pediatric Pulmonology. 1985;1(3, supplement):S69–S76.
    1. Cole CH, Fiascone JM. Strategies for prevention of neonatal chronic lung disease. Seminars in Perinatology. 2000;24(6):445–462.
    1. Bancalari E. Corticosteroids and neonatal chronic lung disease. European Journal of Pediatrics. 1998;157, supplement(1):S31–S37.
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2003;(1) Article ID CD001146.
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2010;(1) Article ID CD001146.
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2003;(1) Article ID CD001144.
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2003;(1) Article ID CD001145.
    1. Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117(1):75–83.
    1. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. American Journal of Obstetrics and Gynecology. 2004;190(4):878–881.
    1. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatric Research. 2001;50(6):706–711.
    1. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114(6):1649–1657.
    1. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews. 2003;(2) Article ID CD002057.
    1. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews. 2003;(1) Article ID CD002058.
    1. Lister P, Iles R, Shaw B, Ducharme F. Inhaled steroids for neonatal chronic lung disease. Cochrane Database of Systematic Reviews. 2000;(3) Article ID CD002311.
    1. Halliday HL, Patterson CC, Halahakoon CWNL. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics. 2001;107(2):232–240.
    1. Dugas MA, Nguyen D, Frenette L, et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics. 2005;115(5):e566–e572.
    1. Suchomski SJ, Cummings JJ. A randomized trial of inhaled versus intravenous steroids in ventilator-dependent preterm infants. Journal of Perinatology. 2002;22(3):196–203.
    1. Viscardi RM, Hasday JD, Gumpper KF, Taciak V, Campbell AB, Palmer TW. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. 1997;156(5):1523–1529.
    1. Watterberg KL, Murphy S, Kelly HW, et al. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. Pediatrics. 1993;91(4):803–806.
    1. Kennedy KA. Epidemiology of acute and chronic lung injury. Seminars in Perinatology. 1993;17(4):247–252.
    1. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database of Systematic Reviews. 2007;(4) Article ID CD000501.
    1. Tyson JE, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. The New England Journal of Medicine. 1999;340(25):1962–1968.
    1. Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised controlled trial of oral vitamin a supplementation in preterm infants to prevent chronic lung disease. Archives of Disease in Childhood. 2001;84(1):F9–F13.
    1. Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005;115(3):e249–e254.
    1. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. New England Journal of Medicine. 1992;326(19):1233–1239.
    1. Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews. 2000;(4) Article ID CD000366.
    1. Mamo LB, Suliman HB, Giles BL, Auten RL, Piantadosi CA, Nozik-Grayck E. Discordant extracellular superoxide dismutase expression and activity in neonatal hyperoxic lung. American Journal of Respiratory and Critical Care Medicine. 2004;170(3):313–318.
    1. Davis JM, Rosenfeld WN, Sanders RJ, Gonenne A. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. Journal of Applied Physiology. 1993;74(5):2234–2241.
    1. Padmanabhan RV, Gudapaty R, Liener IE. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. American Review of Respiratory Disease. 1985;132(1):164–167.
    1. Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. Journal of Clinical Investigation. 1984;73(1):87–95.
    1. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics. 2003;111(3):469–476.
    1. Jain A, Madsen DC, Auld PAM, et al. L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet. Journal of Nutrition. 1995;125(4):851–856.
    1. Ahola T, Lapatto R, Raivio KO, et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. Journal of Pediatrics. 2003;143(6):713–719.
    1. Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biology of the Neonate. 2004;86(4):275–279.
    1. Watts JL, Milner R, Zipursky A, et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants infants less than 1,500 g birth weight. European Respiratory Journal. 1991;4(2):188–190.
    1. Berger TM, Frei B, Rifai N, et al. Early high dose antioxidant vitamins do not prevent bronchopulmonary dysplasia in premature baboons exposed to prolonged hyperoxia: a pilot study. Pediatric Research. 1998;43(6):719–726.
    1. Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics. 2011;127(2):e414–e422.
    1. Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics. 1993;92(4):606–609.
    1. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatric Research. 1994;36(3):402–408.
    1. McCurnin DC, Pierce RA, Ling YC, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2005;288(3):L450–L459.
    1. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics. 1999;103(3):610–618.
    1. Potter CF, Dreshaj IA, Haxhiu MA, Stork EK, Chatburn RL, Martin RJ. Effect of exogenous and endogenous nitric oxide on the airway and tissue components of lung resistance in the newborn piglet. Pediatric Research. 1997;41(6):886–891.
    1. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. New England Journal of Medicine. 2006;355(4):343–353.
    1. Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. New England Journal of Medicine. 2006;355(4):354–364.
    1. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. New England Journal of Medicine. 2003;349(22):2099–2107.
    1. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. 1997;77(3):F185–F190.
    1. Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. The Lancet. 2010;376(9738):346–354.
    1. Van Meurs KP, Hintz SR, Ehrenkranz RA, et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. Journal of Perinatology. 2007;27(6):347–352.
    1. Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics. 2011;128(4):729–739.
    1. Cole FS, Alleyne C, Barks JDE, et al. NIH consensus development conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 2011;127(2):363–369.
    1. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Current Pharmaceutical Design. 2005;11(10):1255–1265.
    1. Shah RV, Mitchell RN. The role of stem cells in the response to myocardial and vascular wall injury. Cardiovascular Pathology. 2005;14(5):225–231.
    1. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. American Journal of Respiratory and Critical Care Medicine. 2009;180(11):1122–1130.
    1. Van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. American Journal of Respiratory and Critical Care Medicine. 2009;180(11):1131–1142.
    1. Abman SH, Matthay MA. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia: delivering the secretome. American Journal of Respiratory and Critical Care Medicine. 2009;180(11):1039–1041.
    1. Thomas W, Speer CP. Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia—what is the evidence? Neonatology. 2008;94(3):150–159.
    1. Laughon MM, Langer JC, Bose CL, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. American Journal of Respiratory and Critical Care Medicine. 2011;183(12):1715–1722.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe